Search Within

Jennifer Kimberly Lue

Formats
  1. Meeting Abstract (36)
  2. Journal Article (10)
  3. Book Section (2)
  4. Research Letter (2)
  5. Review (2)
Groups
  1. Department of Medicine (45)
  2. Hematologic Malignancies, Division of (45)
  3. Center for Hematologic Malignancies (42)
  4. Lymphoma (42)
  5. Hematology-Oncology Fellows (35)
  6. GSK Faculty (32)

More Groups

People
  1. Gilles Salles (44)
  2. Lorenzo Falchi (40)
  3. Maria Palomba (38)
  4. Andrew Zelenetz (36)
  5. Anita Kumar (36)
  6. Paul Hamlin (32)

More People

Years
  1. 2025 (6)
  2. 2024 (22)
  3. 2023 (19)
  4. 2022 (5)
Publications
  1. Blood (33)
  2. Hematological Oncology (3)
  3. Blood Advances (2)
  4. Blood Cancer Journal (2)
  5. Haematologica (2)
  6. Journal of Clinical Oncology (2)

More Publications

Publishers
  1. American Society of Hematology (35)
  2. Wiley Blackwell (5)
  3. American Society of Clinical Oncology (2)
  4. Ferrata Storti Foundation (2)
  5. Nature Publishing Group (2)
  6. Taylor & Francis Group (2)

More Publishers

Results (52)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Mature T-cell and NK-cell lymphoma involvement of the central nervous system: A single center experience
    Journal Article

    Ma, H.; Marchi, E.; O’Connor, O. A.; Lue, J. K.
    Leukemia and Lymphoma (2023)

    Fulltext@MSK | Save
  • TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy
    Journal Article

    Johnson, W. T.; Ganesan, N.; Epstein-Peterson, Z. D.; Moskowitz, A. J.; Stuver, R. N.; Maccaro, C. R.; Galasso, N.; Chang, T.; Khan, N.; Aypar, U.; more...
    Blood Advances (2023)

    Fulltext@MSK | Save
  • Retrospective characterization of nodal marginal zone lymphoma
    Journal Article

    Stuver, R.; Drill, E.; Qualls, D.; Okwali, M.; Batlevi, C. L.; Caron, P. C.; Dogan, A.; Epstein-Peterson, Z. D.; Falchi, L.; Hamlin, P. A.; more...
    Blood Advances (2023)

    Fulltext@MSK | Save
  • Phase 1 trail of KT‐413, a degrader of IRAK4 and IMID substrates, in adult patients with relapsed or refractory B‐cell non‐Hodgkins's lymphomas
    Meeting Abstract

    Lue, J. K.; Stevens, D. A.; Ayers, E.; Dunleavy, K.; Mattour, A.; Mishkin, A.; McDonald, A.; Agarwal, S.; Henrick, P.; Perea, R.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • PET‐adapted therapy with nivolumab plus adriamycin, vinblastine, and dacarbazine for newly diagnosed stage III or IV Hodgkin Lymphoma
    Meeting Abstract

    Moskowitz, A.; Savage, K.; Feldman, T.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Phase 2 trial of nivolumab plus adriamycin, vinblastine, dacarbazine (N‐AVD) as frontline therapy in older adults with Hodgkin lymphoma
    Meeting Abstract

    Torka, P.; Feldman, T.; Savage, K.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Pharmacologic features of drugs targeting BCL2 family members
    Book Section

    Lue, J. K.; O'Connor, O. A.
    In O'Connor, O. A.; Ansell, S. M.; Seymour, J. F. (Eds.) Precision Cancer Therapies (2023)

    Fulltext@MSK | Save
  • Characterization of a large cohort of patients with nodal marginal zone lymphoma shows prolonged survival, time-to-treatment, and time-to-transformation
    Meeting Abstract

    Stuver, R.; Drill, E.; Qualls, D.; Okwali, M.; Batlevi, C. L.; Caron, P. C.; Epstein-Peterson, Z. D.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Molecular profiling across lymphoma subtypes using MSK-impact next generation sequencing
    Meeting Abstract

    Batlevi, C. L.; Drill, E.; Okwali, M.; Ptashkin, R.; Caron, P. C.; Epstein-Peterson, Z. D.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Precision targeting of MYD88 mutant DLBCL using the novel combination of irakimids and BCL2 inhibition
    Meeting Abstract

    Grilo, A. M.; Klaus, C.; McDonald, A.; Gollob, J.; Weiss, M.; O'Connor, O. A.; Salles, G.; Chaudhuri, J.; Lue, J. K.
    Blood (2022)

    Fulltext@MSK | Save